Literature DB >> 10211151

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

E Souêtre1, R M Thwaites, H L Yeardley.   

Abstract

BACKGROUND: While the costs associated with Alzheimer's disease have been shown to be significant, there are few data relating cost of care to severity of the disease. AIMS: We aimed to compare the costs associated with different severities of Alzheimer's disease with those incurred by control subjects over a three-month period.
METHOD: In this cross-sectional, multicentre, naturalistic analysis, non-institutionalised patients with Alzheimer's disease (128), their care-givers (128), and 56 matched controls were interviewed once to establish resource use over the previous three months. Patients were stratified into three severity groups according to their Mini Mental State Examination score. Costs were calculated from the perspective of society as a whole.
RESULTS: Over the three-month period, total mean cost per control subject (387 Pounds) was minor compared with mean cost incurred by patients with mild (6616 Pounds), moderate (10,250 Pounds) and severe (13,593 Pounds) Alzheimer's disease. Indirect cost, mainly time spent by care-givers, was the main cost component in all groups (68.6%), followed by direct medical costs (24.7%).
CONCLUSIONS: The cost of care for an Alzheimer's disease patient is directly related to the severity of the patients illness.

Entities:  

Mesh:

Year:  1999        PMID: 10211151     DOI: 10.1192/bjp.174.1.51

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  20 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 2.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?

Authors:  Sandra Nocera; Dario Bonato; Harry Telser
Journal:  Int J Health Care Finance Econ       Date:  2002-09

Review 4.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 5.  Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  H M Lamb; K L Goa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach.

Authors:  P Fenn; A Gray
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 7.  Donepezil. Pharmacoeconomic implications of therapy.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 8.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.